# FIH XON7 in Advanced/Metastatic Solid Tumors

Source: https://onco.cc/trials/nct06154291/  
OnCo record `nct06154291` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XON7 in advanced solid tumours, run by Xenothera SAS, now recruiting.

## Summary

FIH XON7 in Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT06154291 by Xenothera SAS, with 255 participants planned, started 2023-11-14 and due to reach its primary completion in 2026-12. Interventions recorded: XON7.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06154291
- Phase: 1/2
- Setting: Phase I/II, Multi Center, Open Label, First-in-human, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Anti-tumors Efficacy of the Glyco-humanized Polyclonal Antibody XON7 in Patients With Advanced or Metastatic Solid Tumors
- Sponsor: Xenothera SAS
- Enrolled: 255

## Sources

- ClinicalTrials.gov NCT06154291: https://clinicaltrials.gov/study/NCT06154291

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct06154291.json